



Home | COST Actions | Biomedicine and Molecular Biosciences (BMBS) | Actions | BM1103

- ▶ All Actions
- ▶ **Biomedicine and Molecular Biosciences (BMBS)**
 - In Detail
 - **Actions**
- ▶ Chemistry and Molecular Sciences and Technologies (CMST)
- ▶ Earth System Science and Environmental Management (ESSEM)
- ▶ Food and Agriculture (FA)
- ▶ Forests, their Products and Services (FPS)
- ▶ Individuals, Societies, Cultures and Health (ISCH)
- ▶ Information and Communication Technologies (ICT)
- ▶ Materials, Physics and Nanosciences (MPNS)
- ▶ Transport and Urban Development (TUD)
- ▶ Trans-Domain Proposals

BMBS COST Action BM1103

Arterial spin labelling Initiative in Dementia (AID)

Descriptions are provided by the Actions directly via e-COST.

Dementia is a major clinical challenge with care costs approaching 1% of global GDP. Recent estimates suggest that delaying disease onset by 5 years would halve its prevalence. As new disease-modifying treatments will be specific to causative diseases, expensive and bear significant side effects, early diagnosis of dementia will be essential. Current diagnostic criteria include the use of image-based biomarkers using radiotracers. The AID Action aims at coordinating the development of an alternative and cost-effective tool based on an MRI technique, Arterial Spin Labelling (ASL), to obtain reproducible brain perfusion measurements in dementia patients by bringing together scientists and clinicians from across Europe through the flexibility of the COST mechanism.

The scientific program is centered around four work packages and three workgroups aiming at developing standards, improving the reliability of the technique and as establishing it as a possible clinical trial outcome measure. Development of MRI methods, post-processing tools, protocols of cross-validation, statistical analyses and launch of clinical and comparative studies will be undertaken. The main benefit of this Action will be to provide a cost-effective alternative to radiotracer-based biomarkers, and help care providers throughout Europe balancing the need for early diagnosis of dementia with the necessary healthcare cost containment.

Biomedicine and Molecular Biosciences COST Action BM1103

- ▶ **Description**
- ▶ Parties
- ▶ Management Committee



General Information*

- Chair of the Action:**
[Prof Xavier GOLAY](#) (UK)
- Vice Chair of the Action:**
[Prof Matthias GUENTHER](#) (DE)
- Science officer of the Action:**
[Dr Federica ORTELLI](#)
- Administrative officer of the Action:**
[Ms Jeannette NCHUNG](#)

Downloads*

- Action Fact Sheet
[Download AFS as .RTF](#)
- Memorandum of Understanding
[Download MoU as PDF](#)
- Progress Report
[Download Progress Report as PDF](#)
- Poster
[Download Poster as PDF](#)

Websites*

- Action website:**
www.aslindementia.org
- Domain website:**
<http://www.cost.eu/bmbs>

* content provided by e-COST.
Data is synchronised once per night.

